Comparative evaluation of zinc sulfadiazine and silver sulfadiazine in burn wound infection.
One percent silver sulfadiazine has been commonly used as a topical antimicrobial agent after a burn injury. Incidence of burn wound colonization by Staphylococcus aureus in patients treated with silver sulfadiazine has spurred research for other agents. A topical preparation that contains zinc and sulfadiazine (Zad-G) was evaluated for in vitro antibacterial spectrum and in vivo efficacy. Muscle biopsy specimens of rats treated with Zad-G appear to have fewer colonies of S. aureus than groups treated with silver sulfadiazine. Topical therapy with Zad-G for patients with burns was comfortable, reduced wound infection, and was comparable to therapy with silver sulfadiazine. A topical Zad-G preparation that contains zinc sulfadiazine appears to be an effective alternative to silver sulfadiazine in the treatment of burn wounds.
Fox
C L
CL
College of Physicians and Surgeons, Columbia University, New York, New York 10032.
Rao
T N
TN
Azmeth
R
R
Gandhi
S S
SS
Modak
S
S
D000287:Administration, Topical; D000818:Animals; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D001706:Biopsy; D001835:Body Weight; D002056:Burns / Q000150:complications*; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D007194:India; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D012837:Silver Sulfadiazine / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D013411:Sulfadiazine / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D014946:Wound Infection / Q000150:complications / Q000188:drug therapy*
D013411:Sulfadiazine; D012837:Silver Sulfadiazine